These TAMs not only suppress CD8+ T cell activation, but also significantly reduce synthetic lethal responses in PARPi-treated tumor cells and the production of dsDNA fragments, which are required for dsDNA-mediated, STING-dependent activation of antitumor immunity in the context of PARPi therapy. Here, CD8A is linked to neoplasm.